-
Je něco špatně v tomto záznamu ?
Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases
A. Haleckova, O. Benek, L. Zemanová, R. Dolezal, K. Musilek
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
PubMed
35575048
DOI
10.1002/med.21892
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- mitochondriální nemoci * farmakoterapie MeSH
- mitochondrie metabolismus MeSH
- peptidylprolylisomerasa F * antagonisté a inhibitory MeSH
- přechodový pór mitochondriální permeability MeSH
- transportní proteiny mitochondriální membrány * metabolismus MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Cyclophilin D (CypD) is a key regulator of mitochondrial permeability transition pore (mPTP) opening. This pathophysiological phenomenon is associated with the development of several human diseases, including ischemia-reperfusion injury and neurodegeneration. Blocking mPTP opening through CypD inhibition could be a novel and promising therapeutic approach for these conditions. While numerous CypD inhibitors have been discovered to date, none have been introduced into clinical practice, mostly owing to their high toxicity, unfavorable pharmacokinetics, and low selectivity for CypD over other cyclophilins. This review summarizes current knowledge of CypD inhibitors, with a particular focus on small-molecule compounds with regard to their in vitro activity, their selectivity for CypD, and their binding mode within the enzyme's active site. Finally, approaches for improving the molecular design of CypD inhibitors are discussed.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024636
- 003
- CZ-PrNML
- 005
- 20221031101025.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/med.21892 $2 doi
- 035 __
- $a (PubMed)35575048
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Haleckova, Annamaria $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000236189947
- 245 10
- $a Small-molecule inhibitors of cyclophilin D as potential therapeutics in mitochondria-related diseases / $c A. Haleckova, O. Benek, L. Zemanová, R. Dolezal, K. Musilek
- 520 9_
- $a Cyclophilin D (CypD) is a key regulator of mitochondrial permeability transition pore (mPTP) opening. This pathophysiological phenomenon is associated with the development of several human diseases, including ischemia-reperfusion injury and neurodegeneration. Blocking mPTP opening through CypD inhibition could be a novel and promising therapeutic approach for these conditions. While numerous CypD inhibitors have been discovered to date, none have been introduced into clinical practice, mostly owing to their high toxicity, unfavorable pharmacokinetics, and low selectivity for CypD over other cyclophilins. This review summarizes current knowledge of CypD inhibitors, with a particular focus on small-molecule compounds with regard to their in vitro activity, their selectivity for CypD, and their binding mode within the enzyme's active site. Finally, approaches for improving the molecular design of CypD inhibitors are discussed.
- 650 12
- $a peptidylprolylisomerasa F $x antagonisté a inhibitory $7 D000081406
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mitochondrie $x metabolismus $7 D008928
- 650 12
- $a mitochondriální nemoci $x farmakoterapie $7 D028361
- 650 12
- $a transportní proteiny mitochondriální membrány $x metabolismus $7 D033681
- 650 _2
- $a přechodový pór mitochondriální permeability $7 D000083162
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Benek, Ondrej $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $u University Hospital Hradec Kralove, Biomedical Research Centre, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000168401933
- 700 1_
- $a Zemanová, Lucie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000227325935
- 700 1_
- $a Dolezal, Rafael $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $u University Hospital Hradec Kralove, Biomedical Research Centre, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000194953934
- 700 1_
- $a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000275044062
- 773 0_
- $w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 42, č. 5 (2022), s. 1822-1855
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35575048 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031101022 $b ABA008
- 999 __
- $a ok $b bmc $g 1854395 $s 1175926
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 42 $c 5 $d 1822-1855 $e 20220516 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
- LZP __
- $a Pubmed-20221017
